成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Saudi Pharmaceutical Journal >>article
Saudi Pharmaceutical Journal

Saudi Pharmaceutical Journal

IF: 3
Download PDF

A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer

Published:1 September 2018 DOI: 10.1016/j.jsps.2018.04.010 PMID: 30202213
Silky Bedi , Shah A. Khan , Majed M. AbuKhader , Perwez Alam , Nasir A. Siddiqui , Asif Husain

Abstract

The mortality rate in patients suffering from non-small cell lung cancer (NSCLC) is quite high. This type of cancer mainly occurs due to rearrangements in the anaplastic lymphoma kinase (ALK) gene which leads to form an oncogene of fused gene NPM-ALK. Brigatinib is recently approved by FDA in April 2017 as a potent tyrosine kinase inhibitor (TKI) for the NSCLC therapy. In the present scenario, it is no less than a wonder drug because it is indicated for the treatment of advanced stages of metastatic ALK positive NSCLC, a fatal disease to overcome the resistance of various other ALK inhibitors such as crizotinib, ceritinib and alectinib. In addition to ALK, it is also active against multiple types of kinases such as ROS1, Insulin like growth factor-1Receptor and EGFR. It can be synthesized by using N-[2-methoxy-4-[4-(dimethylamino) piperidin-1-yl] aniline] guanidine and 2,4,5-trichloropyrimidine respectively in two different ways. Its structure consists of mainly dimethylphosphine oxide group which is responsible for its pharmacological activity. It is active against various cell lines such as HCC78, H2228, H23, H358, H838, U937, HepG2 and Karpas- 299. Results of ALTA (ALK in Lung Cancer Trial of AP26113) phase ? trial shows that 90?mg of brigatinib for 7?days and then 180?mg for next days is effective in the treatment of NSCLC. Brigatinib has been shown to have favorable risk benefit profile and is a safer drug than the available cytotoxic chemotherapeutic agents. In comparison to other FDA approved drugs for the same condition, it causes fewer minor adverse reactions which can be easily managed either by changing the dose or by providing good supportive care. This article is intended to provide readers with an overview of chemistry, pharmacokinetic, pharmacodynamic and safety profile of brigatinib, which addresses an unmet medical need.

Substances (6)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Crizotinib 877399-52-5 C21H22Cl2FN5O 553 suppliers $5.00-$1963.50
2,4,5-Trichloropyrimidine 5750-76-5 C4HCl3N2 429 suppliers $5.00-$1327.65
Ceritinib (LDK378) 1032900-25-6 C28H36ClN5O3S 417 suppliers $25.00-$3600.00
Alectinib 1256580-46-7 C30H34N4O2 316 suppliers $35.00-$1504.50
Brigatinib 1197953-54-0 C29H39ClN7O2P 308 suppliers $5.00-$1504.50
DIMETHYLPHOSPHINE OXIDE 7211-39-4 C2H7OP 164 suppliers $6.00-$2700.00

Similar articles

IF:9.6

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Cancer treatment reviews Jordi Remon , Lizza E.L. Hendriks ,etc Published: 1 November 2020
IF:12.7

Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.

ACS Central Science Sabrina Baltschukat, Barbara Schacher Engstler,etc Published: 15 May 2019